In addition, the reduced expression of Parkin is closely related to its promoter’s hypermethylation, thus the abnormal methylation of the Parkin promoter potentially contributes to the pathogenesis of CML and ALL. Here, PRKN is linked to chronic myelogenous leukemia, BCR-ABL1 positive.